Apellis Pharmaceuticals Engaging with Investors
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a leading biotech innovator, is gearing up for an exciting series of investor conferences. These events are designed to share insights about their groundbreaking advancements in complement science and how they plan to transform treatment for serious diseases. As a forward-thinking biopharmaceutical company, Apellis is committed to developing therapies that can bring real change to patients’ lives.
Key Upcoming Conferences
During this important time, Apellis will be participating in several key investor conferences that provide a platform for their management to present and engage with diverse investor audiences. These conferences include:
Wells Fargo Healthcare Conference
This event is scheduled for Wednesday, September 3, and will kick off at 8:45 a.m. ET. It is an excellent opportunity for investors to learn about the company’s strategy and future roadmap directly from its leadership.
Cantor Global Healthcare Conference
Following closely, Apellis will take part in the Cantor Global Healthcare Conference on Thursday, September 4, starting at 8:35 a.m. ET. This conference will allow Apellis to showcase their innovative solutions to health challenges faced by patients.
Baird Global Healthcare Conference
On Tuesday, September 9, at 10:15 a.m. ET, Apellis will present at the Baird Global Healthcare Conference. These presentations are crucial for connecting with investors who are eager to learn more about the potential impact of their therapies.
Interactive Conference Experience
For those who are unable to attend the conferences, Apellis ensures that the live webcasts of their presentations will be accessible via the “Events and Presentations” section on their website. Typically, a recorded replay of these sessions will be available for about 30 days post-event, allowing investors the flexibility to catch up on any missed information.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals is at the forefront of complement science, having introduced the first new class of complement medicine in over a decade. Their dedicated research and development efforts have resulted in two C3-targeting therapies currently approved for various serious conditions, including geographic atrophy, a leading cause of blindness, and severe kidney diseases like C3G and primary IC-MPGN.
Their dedication to innovation extends beyond existing products, as Apellis actively seeks to explore the vast potential of C3-targeted therapies across numerous serious health issues.
Investor Relations
For inquiries or further information, interested individuals can reach out to Apellis Pharmaceuticals' Investor Contact:
Eva Stroynowski
Email: eva.stroynowski@apellis.com
Phone: 617.938.6229
Frequently Asked Questions
What is Apellis Pharmaceuticals known for?
Apellis Pharmaceuticals is known for its pioneering work in complement science and developing therapies for serious diseases, including eye and kidney conditions.
When are the upcoming investor conferences?
The conferences are scheduled for September 3, 4, and 9, with specific times for each event.
How can investors access the conference webcasts?
Investors can access the live webcasts through the “Events and Presentations” section on Apellis' website, with replays available for 30 days.
What types of therapies does Apellis offer?
Apellis offers C3-targeting therapies that treat diseases such as geographic atrophy and severe kidney diseases, with ongoing research into additional applications.
Who can be contacted for investor inquiries?
Investor inquiries can be directed to Eva Stroynowski at Apellis Pharmaceuticals via email or phone.
